Clinigen Group PLC (LON:CLIN) has been given an average recommendation of “Buy” by the six analysts that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is GBX 1,200.83 ($16.08).

Several brokerages have issued reports on CLIN. Peel Hunt reissued an “add” rating and issued a GBX 1,200 ($16.07) price target on shares of Clinigen Group in a research note on Wednesday, September 13th. N+1 Singer reissued a “buy” rating and issued a GBX 1,225 ($16.41) price target on shares of Clinigen Group in a research note on Wednesday. Royal Bank Of Canada reissued an “outperform” rating and issued a GBX 1,360 ($18.21) price target on shares of Clinigen Group in a research note on Tuesday, November 7th. Finally, Berenberg Bank began coverage on Clinigen Group in a research note on Wednesday, November 1st. They issued a “hold” rating and a GBX 1,200 ($16.07) price target on the stock.

In other news, insider John Bacon sold 250,000 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of GBX 1,093 ($14.64), for a total transaction of £2,732,500 ($3,659,434.85). Also, insider Shaun Edward Chilton sold 100,000 shares of the business’s stock in a transaction that occurred on Friday, October 13th. The shares were sold at an average price of GBX 1,150 ($15.40), for a total value of £1,150,000 ($1,540,109.82). In the last 90 days, insiders have sold 354,955 shares of company stock valued at $393,289,235.

Clinigen Group (LON:CLIN) opened at GBX 1,018 ($13.63) on Friday. Clinigen Group has a 12 month low of GBX 700 ($9.37) and a 12 month high of GBX 1,187 ($15.90).

Clinigen Group (LON:CLIN) last posted its quarterly earnings data on Thursday, September 28th. The company reported GBX 41.80 ($0.56) EPS for the quarter, topping the Zacks’ consensus estimate of GBX 41.20 ($0.55) by GBX 0.60 ($0.01). Clinigen Group had a return on equity of 0.98% and a net margin of 0.70%. The company had revenue of £302.30 million for the quarter.

The company also recently disclosed a dividend, which was paid on Friday, December 1st. Stockholders of record on Thursday, November 9th were issued a dividend of GBX 3.40 ($0.05) per share. This is an increase from Clinigen Group’s previous dividend of $1.60. The ex-dividend date of this dividend was Thursday, November 9th. This represents a dividend yield of 0.32%.

ILLEGAL ACTIVITY NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/12/02/clinigen-group-plc-clin-given-consensus-rating-of-buy-by-brokerages.html.

About Clinigen Group

Analyst Recommendations for Clinigen Group (LON:CLIN)

Receive News & Ratings for Clinigen Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.